Labels: FDA, intentional obfuscation, scandals, Vioxx, Washington Post
Related posts
Bioethics’ Identity Crisis: Are We Asking It to Be What It Is Not?
This editorial appears in the May 2025 issue of the American Journal of Bioethics. As the “bio” in “bioethics” suggests, the topics under the purview of bioethics have expanded to include issues that affect our health and well-being that extend beyond clinical settings. This is largely due to our growing understanding of the social, political, cultural, […]
A Patient-Directed Approach: How the U.S. Model of Medical Aid in Dying Balances Compassion with Safeguards
This editorial appears in the May 2025 issue of the American Journal of Bioethics. Medical aid in dying (MAID) is an important and highly sensitive aspect of end-of-life care reflecting broad ethical considerations. Internationally, approaches to assisted dying vary dramatically in accordance with legal developments, cultural norms, and local advocacy. Medical aid in dying in the […]
A Pioneering Industry-Academia Collaboration Celebrates 10 Years
In May 2015, Johnson & Johnson (J&J) and the Division of Medical Ethics at New York University Grossman School of Medicine (DME) embarked on a novel pilot program to support equitable expanded-access allocation of a J&J investigational medicine. Expanded access (EA), also known as compassionate use, is a treatment pathway, regulated by health authorities, to […]
The Community Becomes the Ethics Committee
In my roles at Columbia University Medical Center (CUMC), I often find myself bridging two worlds: the academic and the communal. As a Senior Research Staff Associate managing a longitudinal study on aging dementia and a member of the New York Presbyterian Adult Clinical Ethics Committee, I have come to learn a truth that many […]